Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More

(Page 2 of 2)

paperwork targeting an $85 million IPO.

—German cancer drug developer BioNTech (NASDAQ: BNTX) went public, but only after lowering the price and the number of shares in its IPO.

—South San Francisco, CA-based cancer drug developer Five Prime Therapeutics (NASDAQ: FPRX) is laying off approximately 70 employees. The move comes nine months after a shakeup that cut 41 positions and less than one month after CEO Aron Knickerbocker resigned.

—Xconomy will host two life sciences events next week: The New York Breed of Startups, on Oct. 15, and Boston’s Life Science Disruptors, on Oct. 17.


—Genentech’s Merdad Parsey is leaving to become chief medical officer of Gilead Sciences (NASDAQ: GILD) … Verve Therapeutics appointed Andrew Bellinger chief scientific officer … Stephen Brady joined Tempest Therapeutics as president and chief operating officer … BioMarin Pharmaceutical (NASDAQ: BMRN) promoted Lon Cardon to chief scientific strategy officer … Cue Biopharma (NASDAQ: CUE) promoted Anish Suri to president. He will remain chief scientific officer … and Matthew Young is leaving Jazz Pharmaceuticals (NASDAQ: JAZZ) to become chief operating officer and chief financial officer of Grail.

Ben Fidler, Frank Vinluan, and Sarah de Crescenzo contributed to this report.

Photo “Sunset” by Tom Hall via Creative Commons 2.0.

Single PageCurrently on Page: 1 2 previous page